Kalaris Therapeutics, Inc. Common Stock (KLRS) is a publicly traded Healthcare sector company. As of May 21, 2026, KLRS trades at $4.83 with a market cap of $112.78M and a P/E ratio of -10.39. KLRS moved +3.09% today. Year to date, KLRS is -40.95%; over the trailing twelve months it is +45.05%. Its 52-week range spans $2.14 to $12.90. Analyst consensus is strong buy with an average price target of $15.75. Rallies surfaces KLRS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Kalaris Secures $104.9M Cash Runway and Advances TH103 Phase 1b/2 Trial: Kalaris held $104.9 million in cash and marketable securities as of March 31, 2026, expected to fund operations into Q4 2027. Patient screening for its Phase 1b/2 multiple ascending dose trial of TH103 is underway, with preliminary data due 1H 2027 and Phase 3 planned by year-end 2027.
| Metric | Value |
|---|---|
| Price | $4.83 |
| Market Cap | $112.78M |
| P/E Ratio | -10.39 |
| EPS | $-0.46 |
| Dividend Yield | 0.00% |
| 52-Week High | $12.90 |
| 52-Week Low | $2.14 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-10.86M |
| Gross Margin | 0.00% |
5 analysts cover KLRS: 0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $15.75.